Shares of Evolus Inc. (EOLS) surged 5.12% on Wednesday, outperforming the broader market in an intraday session marked by optimism surrounding the company's impressive preliminary fourth-quarter 2024 performance and promising growth prospects.
The biopharmaceutical company's stock rallied after reporting strong preliminary Q4 2024 results, with sales of $79 million, a 30% year-over-year increase that surpassed expectations. Investors were buoyed by Evolus' robust growth outlook, as the company projects net revenues of $345 million to $355 million in 2025, representing a 30% to 33% growth from 2024.
Additionally, Evolus' upcoming product launches, including FDA approvals for Evolysse Form and Evolysse Smooth, have further fueled investor confidence in the company's ability to sustain its earnings and revenue growth trajectory. With these promising developments, market sentiment surrounding Evolus' prospects has strengthened, driving the stock's upward momentum on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.